BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Shows Superior Progression-Free Survival in Biomarker-Positive NSCLC Patients

Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan demonstrated meaningfully greater magnitude of progression-free survival benefit in p...

September 09, 2024 | News

Acepodia Partners with Pfizer Ignibiolote to Advance Cell Therapies for Autoimmune Diseases and Oncology

Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyon...

September 04, 2024 | News

Simcere Zaiming and TargetRx Forge Strategic Partnership for Groundbreaking ALK/ROS1 Dual Inhibitor in China

Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx In...

September 03, 2024 | News

Noetik Secures $40M in Oversubscribed Series A to Advance AI-Driven Cancer Therapeutics

Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therape...

September 02, 2024 | News

Guardant Health Japan Secures MHLW Approval for Guardant360® CDx as First Blood-Based Companion Diagnostic for EGFR Exon 20 NSCLC Mutations

Guardant Health Japan , a leading precision oncology company, announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan&nbs...

August 30, 2024 | News

Zuellig Pharma Secures Exclusive Distribution Agreement with Regeneron to Launch Libtayo® in South Korea and Taiwan

Zuellig Pharma, a leading healthcare solutions company in Asia, has announced an exclusive distribution agreement with Regeneron Ireland DAC, a wholly owne...

August 28, 2024 | News

HKBU Research Identifies Phosphocholine as a Potential Therapy for PM2.5-Related Lung Damage

A research team led by Hong Kong Baptist University (HKBU) has discovered that phosphocholine, an important component in the body's metabolism, c...

August 28, 2024 | News

Everest Medicines Launches First Clinical Trial for Personalized mRNA Cancer Vaccine EVM16 in China

Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeut...

August 22, 2024 | News

GE HealthCare and Roche Diagnostics Partner to Transform Precision Cancer Care in Asia Pacific

GE HealthCare and Roche Diagnostics have entered into a Memorandum of Understanding (MOU) that will leverage the strengths and resources of both comp...

August 22, 2024 | News

Kelun-Biotech's NDA for Sacituzumab Tirumotecan Accepted by China's NMPA Following Positive Lung Cancer Study Results

New drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) based on the positive results from the pivotal O...

August 21, 2024 | News

Boston Immune Technologies and Therapeutics Secures Strategic Agreement with Otsuka's MSRD and $4M NIH/NCI Grant for Advancing Antibody Development

Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist...

August 19, 2024 | News

Akeso’s Ivonescimab Granted Priority Review by China's NMPA for First-Line Treatment of PD-L1 Positive NSCLC

Akeso, Inc. announced that the National Center for Drug Evaluation of the State Drug Administration of the People's Republic of China (NMPA CDE) ...

August 15, 2024 | News

Alfred Health Expands Oracle EHR to Enhance Cancer Care and Clinical Trial Access

Leading Victorian healthcare network, Alfred Health, has extended its long-standing Oracle Health footprint with Oracle's Oncology electroni...

August 14, 2024 | News

Angiex Initiates Patient Dosing in Phase 1 Clinical Trial of AGX101, a First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for Solid Cancers

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for t...

August 12, 2024 | News

Stay Connected